

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TM1/22 - Tumour Markers

Deadline: 08.02.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability						
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}
(208) beta-2-microglobulin					11						10	10	100%
Samples and groups	[mg/L]												
Sample A		1,38	0,081	5,8	11						10	10	100%
Other					11	0					10		
							1x 4/29, 1x 6/1, 2x 6/58, 2x 6/60, 1x 6/75, 1x 6/91, 2x 6/149, 1x 6/179						
Sample B		3,31	0,22	6,7	11						10	10	100%
Other					11	0					10		
							1x 4/29, 1x 6/1, 2x 6/58, 2x 6/60, 1x 6/75, 1x 6/91, 2x 6/149, 1x 6/179						
(185) AFP					14						14	13	93%
Samples and groups	[µg/L]												
Sample A		104	10	9,8	14						14	13	93%
Other					14	0					14		
							4x 4/1, 3x 4/12, 4x 4/60, 3x 4/179						
Sample B		20,3	2,1	11	14						14	13	93%
Other					14	0					14		
							4x 4/1, 3x 4/12, 4x 4/60, 3x 4/179						
(181) CA 15-3					13						13	12	92%
Samples and groups	[kU/L]												
Sample A		12,5	1,5	12	13						13	12	92%
Other					13	0					13		
							4x 4/1, 2x 4/12, 4x 4/60, 3x 4/179						
Sample B		49,6	11	23	13						13	13	100%
Other					13	0					13		
							4x 4/1, 2x 4/12, 4x 4/60, 3x 4/179						
(182) CA 19-9					15						15	15	100%
Samples and groups	[kU/L]												
Sample A		112	100	92	15						15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		42,7	3,1	7,2	5	0	CVPG	43,2	0,35	20%	34,5	51,9	5
Other					10	0					10		
								4x 4/1, 3x 4/12, 3x 4/179					
Sample B		264	280	110	15						15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		72,7	5,9	8,1	5	0	CVPG	74,4	0,64	20%	59,5	89,3	5
Other					10	0					10		
								4x 4/1, 3x 4/12, 3x 4/179					
(183) CA 72-4					14						14	11	79%
Samples and groups	[kU/L]												
Sample A		1,58	0,18	11	14						14	11	79%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		1,58	0,18	11	14	0	CVPG	1,38	0,032	22%	1,07	1,69	14
Sample B		2,79	0,16	5,9	14						14	12	86%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		2,79	0,16	5,9	14	0	CVPG	2,67	0,032	22%	2,08	3,26	14
(180) CA 125					15						15	15	100%
Samples and groups	[kU/L]												
Sample A		26,3	6,0	23	15						15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		31,8	1,3	4,2	5	0	CVPG	31,7	0,34	20%	25,3	38,1	5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		27,7	0,82	2,9	5	0	CVPG	27,6	0,23	20%	22	33,2	5
Other					5	0					5		
								2x 4/12, 3x 4/179					
Sample B		12,1	2,1	17	15						15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		14,1	0,53	3,7	5	0	CVPG	14,3	0,24	20%	11,4	17,2	5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		12,3	0,32	2,6	5	0	CVPG	11,9	0,10	20%	9,52	14,3	5
Other					5	0					5		
								2x 4/12, 3x 4/179					
(189) CEA					15						15	15	100%
Samples and groups	[µg/L]												
Sample A		4,62	0,53	12	15						15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		4,73	0,089	1,9	5	0	CVPG	4,71	0,039	16%	3,95	5,47	5
Other					10	0					10		
								4x 4/1, 3x 4/12, 3x 4/179					
Sample B		8,42	0,95	11	15						15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		7,45	0,22	2,9	5	0	CVPG	7,25	0,054	16%	6,09	8,41	5

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TM1/22 - Tumour Markers

Deadline: 08.02.2022

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(189) CEA					15							15	15	100%
Samples and groups	[µg/L]													
Sample B		8,42	0,95	11	15							15	15	100%
Other					10	0						10		
							4x 4/1, 3x 4/12, 3x 4/179							
(184) CYFRA 21-1					12							12	11	92%
Samples and groups	[µg/L]													
Sample A		7,19	1,0	14	12							12	11	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		7,66	0,48	6,3	8	0	CVPG	7,28	0,080	18%	5,96	8,6	8	
(60) Roche														
Other					4	0							4	
							4x 4/1							
Sample B		9,83	1,4	14	12							12	11	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		10,6	0,71	6,7	8	0	CVPG	10,3	0,15	18%	8,44	12,2	8	
(60) Roche														
Other					4	0							4	
							4x 4/1							
(186) hCG					15							15	14	93%
Samples and groups	[U/L]													
Sample A		181	25	14	15							15	14	93%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		192	8,1	4,2	5	0	CVPG	190	14	18%	155	225	5	
(210) Roche HCG STAT														
Other					10	0							10	
							1x 4/1, 3x 4/12, 3x 4/60, 3x 4/179							
Sample B		471	88	19	15							15	14	93%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		507	14	2,8	5	0	CVPG	494	47	18%	405	583	5	
(210) Roche HCG STAT														
Other					10	0							10	
							1x 4/1, 3x 4/12, 3x 4/60, 3x 4/179							
(206) Calcitonin					2							2	1	50%
Samples and groups	[ng/L]													
Sample A		28,9	8,8	30	2							2	1	50%
Other					2	0							2	
							1x 4/29, 1x 4/60							
Sample B		2,90	0,90	31	2							2	1	50%
Other					2	0							2	
							1x 4/29, 1x 4/60							
(194) NSE					13							12	11	92%
Samples and groups	[µg/L]													
Sample A		191	15	7,8	13							12	11	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		192	14	7,3	12	0	CVPG	174	3,1	30%	121	227	12	
(60) Roche														
Other					1	0							0	
							1x 4/1							
Sample B		4,97	0,37	7,4	13							12	11	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		5,02	0,33	6,6	12	0	CVPG	4,65	0,079	30%	3,25	6,05	12	
(60) Roche														
Other					1	0							0	
							1x 4/1							
(191) PSA					15							15	14	93%
Samples and groups	[µg/L]													
Sample A		3,15	0,40	13	15							15	14	93%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		3,51	0,030	0,85	5	0	CVPG	3,49	0,020	15%	2,96	4,02	5	
(60) Roche														
Other					10	0							10	
							4x 4/1, 2x 4/12, 3x 4/179, 1x 4/195							
Sample B		3,53	0,37	10	15							15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		3,83	0,045	1,2	5	0	CVPG	3,81	0,023	15%	3,23	4,39	5	
(60) Roche														
Other					10	0							10	
							4x 4/1, 2x 4/12, 3x 4/179, 1x 4/195							
(198) free-PSA					10							10	9	90%
Samples and groups	[µg/L]													
Sample A		2,21	0,28	13	10							10	9	90%
Other					10	0							10	
							4x 4/1, 3x 4/60, 2x 4/179, 1x 4/195							
Sample B		2,55	0,28	11	10							10	9	90%
Other					10	0							10	
							4x 4/1, 3x 4/60, 2x 4/179, 1x 4/195							
(201) S-100					6							6	5	83%
Samples and groups	[µg/L]													
Sample A		0,750	0,025	3,3	6							6	5	83%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		0,750	0,025	3,3	6	0	CVPG	0,744	,0067	32%	0,505	0,983	6	
(60) Roche														
Sample B		0,044	0,008	20	6							6	5	83%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		0,044	0,008	20	6	0	CVPG	0,04		±0,013	0,027	0,053	6	
(60) Roche														

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TM1/22 - Tumour Markers

Deadline: 08.02.2022

Test	[unit]						Comparability						N _{eva}	N _{suc}	S _{rel}
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL				
(195) SCCA					8							8	7	88%	
Samples and groups	[µg/L]														
Sample A		1,30	0,30	23	8							8	7	88%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		1,30	0,30	23	5	0	CVPG	1,03	0,048	±0,7	0,33	1,73	5		
(1) Abbott															
Other					3	0						3			
Sample B		1,19	0,28	24	8							8	8	100%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		1,10	0,15	13	5	0	CVPG	0,984	0,043	±0,706	0,284	1,69	5		
(1) Abbott															
Other					3	0						3			
(207) Thyreoglobulin					5							5	5	100%	
Samples and groups	[µg/L]														
Sample A		166	2,1	1,3	5							5	5	100%	
Other					5	0						5			
Sample B		10,3	1,9	19	5							5	5	100%	
Other					5	0						5			

st_kn_p

End of report

Printed: 15.02.2022